Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration

Next Previous
Trial Profile

A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceritinib (Primary)
  • Indications Brain metastases; Breast cancer; Glioblastoma; Head and neck cancer; Malignant melanoma
  • Focus Pharmacokinetics

Most Recent Events

  • 26 Oct 2021 Results assessing tumor pharmacokinetics and tumor pharmacodynamics of ceritinib in patients with brain metastasis or recurrent glioblastoma published in the Clinical Cancer Research
  • 10 Dec 2020 Status changed from active, no longer recruiting to completed.
  • 15 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Mar 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top